Krähenbühl S - Search Results

1

ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor.

Seeland S, Kettiger H, Murphy M, Treiber A, Giller J, Kiss A, Sube R, Krähenbühl S, Hafner M, Huwyler J. Seeland S, et al. Among authors: krahenbuhl s. Pharmacol Res Perspect. 2015 Mar;3(2):e00123. doi: 10.1002/prp2.123. Epub 2015 Mar 12. Pharmacol Res Perspect. 2015. PMID: 26038699 Free PMC article.

2

Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects.

Schnyder A, Krähenbühl S, Drewe J, Huwyler J. Schnyder A, et al. Among authors: krahenbuhl s. J Drug Target. 2005 Jun;13(5):325-35. doi: 10.1080/10611860500206674. J Drug Target. 2005. PMID: 16199376

3

Tumor targeting using liposomal antineoplastic drugs.

Huwyler J, Drewe J, Krähenbuhl S. Huwyler J, et al. Among authors: krahenbuhl s. Int J Nanomedicine. 2008;3(1):21-9. Int J Nanomedicine. 2008. PMID: 18488413 Free PMC article. Review.

4

The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies.

Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J. Poller B, et al. Among authors: krahenbuhl s. J Neurochem. 2008 Dec;107(5):1358-68. doi: 10.1111/j.1471-4159.2008.05730.x. J Neurochem. 2008. PMID: 19013850 Free article.

5

Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. Poller B, et al. Among authors: krahenbuhl s. Cell Mol Neurobiol. 2010 Jan;30(1):63-70. doi: 10.1007/s10571-009-9431-1. Epub 2009 Jul 23. Cell Mol Neurobiol. 2010. PMID: 19629677

6

Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME. Hysek CM, et al. Among authors: krahenbuhl s. PLoS One. 2012;7(5):e36476. doi: 10.1371/journal.pone.0036476. Epub 2012 May 4. PLoS One. 2012. PMID: 22574166 Free PMC article. Clinical Trial.

7

Drug interaction potential of resveratrol.

Detampel P, Beck M, Krähenbühl S, Huwyler J. Detampel P, et al. Among authors: krahenbuhl s. Drug Metab Rev. 2012 Aug;44(3):253-65. doi: 10.3109/03602532.2012.700715. Drug Metab Rev. 2012. PMID: 22788578 Review.

8

Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes.

Detampel P, Witzigmann D, Krähenbühl S, Huwyler J. Detampel P, et al. Among authors: krahenbuhl s. J Drug Target. 2014 Oct 7;22(3):232-241. doi: 10.3109/1061186X.2013.860982. Epub 2013 Dec 13. J Drug Target. 2014. PMID: 24328572

9

CombiCap: A novel drug formulation for the basel phenotyping cocktail.

Camblin M, Berger B, Haschke M, Krähenbühl S, Huwyler J, Puchkov M. Camblin M, et al. Among authors: krahenbuhl s. Int J Pharm. 2016 Oct 15;512(1):253-261. doi: 10.1016/j.ijpharm.2016.08.043. Epub 2016 Aug 24. Int J Pharm. 2016. PMID: 27566010

10

Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J. Kiene K, et al. Among authors: krahenbuhl s. Eur J Pharm Sci. 2019 Jul 1;135:77-82. doi: 10.1016/j.ejps.2019.05.010. Epub 2019 May 16. Eur J Pharm Sci. 2019. PMID: 31102650 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters